Latest News & Features
Americas
Law firm Fitzpatrick, Cella, Harper, & Scinto will begin the New Year with three new faces in its partnership. 19 December 2014
Americas
A US biotechnology company that was on the winning side of an EU court ruling surrounding the patentability of certain organisms has said it “clears the way” for patents in Europe. 19 December 2014
article
The battle between innovative pharma companies and generic drug rivals is a constant source of interest. 19 December 2014
Big Pharma
A decision by the CJEU on a Latvian case should make it easier in the future to challenge an MA granted for a generic version of a reference product, as Trevor Cook of WilmerHale explains. 19 December 2014
Europe
Bringing a ‘repurposed’ drug to market requires a clear patent strategy, but clarity is unfortunately lacking in this field, say Simon Kremer and Rachel Jones of law firm Mewburn Ellis. 19 December 2014
Americas
Maximising the strength of patent protection should be an important objective of any R&D pharma company. Christine Goddard and Janis Fraser of law firm Fish & Richardson offer their six top tips for success. 19 December 2014
Europe
Europe’s highest court has said that an organism incapable of developing into a human does not constitute a human embryo and therefore uses of it can be patented. 18 December 2014
Big Pharma
France-based pharmaceutical company Flamel Technologies has moved its IP to Ireland. 18 December 2014
Americas
The US Patent and Trademark Office has issued new guidance for determining what claims are eligible for patenting, with one lawyer saying it could “muddy the waters”. 17 December 2014
Asia
Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company. 16 December 2014